Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) have earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $43.7273.

COGT has been the subject of a number of research analyst reports. Piper Sandler upped their price objective on Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Robert W. Baird set a $35.00 price objective on Cogent Biosciences in a report on Thursday, February 19th. Jefferies Financial Group initiated coverage on Cogent Biosciences in a report on Monday, March 16th. They set a “buy” rating and a $55.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Finally, Wall Street Zen downgraded Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 31st.

Institutional Trading of Cogent Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in COGT. EverSource Wealth Advisors LLC increased its holdings in shares of Cogent Biosciences by 1,164.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after buying an additional 652 shares during the last quarter. Osaic Holdings Inc. increased its holdings in Cogent Biosciences by 41.4% in the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock valued at $33,000 after purchasing an additional 1,333 shares in the last quarter. Strs Ohio acquired a new stake in Cogent Biosciences in the 1st quarter valued at $36,000. Global Retirement Partners LLC acquired a new stake in Cogent Biosciences in the 4th quarter valued at $37,000. Finally, Parallel Advisors LLC acquired a new stake in Cogent Biosciences in the 1st quarter valued at $39,000.

Cogent Biosciences Trading Up 2.5%

Shares of Cogent Biosciences stock opened at $35.38 on Friday. Cogent Biosciences has a fifty-two week low of $5.03 and a fifty-two week high of $43.73. The firm has a market cap of $6.05 billion, a PE ratio of -16.30 and a beta of 0.37. The business’s fifty day moving average is $35.27 and its two-hundred day moving average is $36.72. The company has a quick ratio of 15.14, a current ratio of 15.14 and a debt-to-equity ratio of 0.41.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) EPS for the quarter, hitting analysts’ consensus estimates of ($0.53). Analysts anticipate that Cogent Biosciences will post -2.23 earnings per share for the current year.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.